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Snake Oil in Your Pomegranate Juice:
Food Health Claims and the FTC
By ALEXANDRA LEDYARD*
Introduction
A COMPANY’S CLAIM that its food or food components provide
health and wellness benefits is certainly not a novel idea. Hippocrates
espoused, “[l]et food be thy medicine and medicine be thy food,” well
over two thousand years ago.1 Fueled by various factors, including
rapid advances in science and technology, increasing healthcare costs,
and an aging population, it is now receiving renewed interest.2 In fact,
food masquerading as drugs is one of today’s hottest trends.3 Whether
it is oatmeal to lower cholesterol,4 yogurt to regulate digestion,5 or
pomegranate juice to take care of your heart,6 so called “functional
foods,”7 foods that provide a health benefit beyond basic nutrition are
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1. Patricia Fitzgerald, Let Food be Thy Medicine: Top 10 Healing Foods of the Decade, HUF-
FINGTON POST (Dec. 30, 2009), http://www.huffingtonpost.com/dr-patricia-fitzgerald/let-
food-be-thy-medicine_b_406582.html.
2. INT’L FOOD INFO. COUNCIL FOUND., FUNCTIONAL FOODS (2011), available at http://
www.foodinsight.org/Content/3842/FinalFunctionalFoodsBackgrounder.pdf.
3. Matthew Herper & Rebecca Ruiz, Snake Oil in Your Snacks, FORBES (June 7, 2010),
http://www.forbes.com/forbes/2010/0607/health-probiotics-vitamins-supplements-snake-
oil-in-snacks.html.
4. How Oats Work, QUAKEROATS.COM, http://www.quakeroats.com/oats-do-more/for-
your-heart/cholesterol/how-oats-work.aspx (last visited Mar. 3, 2012).
5. Lauren Sandler, Gut Instinct: What Health Benefits, Exactly, is Activia Yogurt Supposed
to Offer?, SLATE (July 3, 2008), http://www.slate.com/articles/news_and_politics/hey_wait_
a_minute/2008/07/gut_instinct.html.
6. Brindusa Vanta, Is Pomegranate Juice Good for Your Heart?, LIVESTRONG.COM (Dec.
27, 2010), http://www.livestrong.com/article/343553-is-pomegranate-juice-good-for-your-
heart/.
7. Although the term “functional foods” is not legally defined by the Food, Drug,
and Cosmetic Act (“FDCA”), the term is informally defined for purposes of marketing as
“foods or food components that provide a health benefit beyond basic nutrition.” Gregory
Connolly, Functional Foods Provide More than Just Nutrition, USA TODAY (Aug 3, 2011), http:/
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big business. With annual sales between $20 and $30 billion,8 func-
tional foods comprise roughly five percent of the overall United States
food market, and according to industry experts, functional food reve-
nues are expected to soar.9 In order to capitalize on this trend of
health-conscious consumerism, advertisers have begun aggressively
touting their products’ alleged health benefits.10
In response, the Federal Trade Commission (“FTC”), tasked with
preventing fraudulent, deceptive, and unfair business practices, is
cracking down on advertisers’ dubious or exaggerated health-related
claims. One brand in particular that has caught the attention of the
FTC is POM Wonderful, a manufacturer of pomegranate juice and
extract. Owned by California billionaires Stewart and Lynda Resnick,11
POM Wonderful created a $250 million market12 for pomegranate
juice in just under a decade.13 POM’s eye-catching print advertise-
ments, one of which featured its distinctively curvaceous POM Won-
derful bottle with a noose around its neck, accompanied by the phrase
“Cheat Death,” claimed that the juice can “help prevent premature
/yourlife.usatoday.com/fitness-food/diet-nutrition/story/2011/08/Functional-foods-pro-
vide-more-than-just-nutrition/49791906/1.
8. PRICEWATERHOUSECOOPERS, LEVERAGING GROWTH IN THE EMERGING FUNCTIONAL
FOODS INDUSTRY: TRENDS AND MARKET OPPORTUNITIES 5 (2009), available at http://www.
pwc.com/us/en/transaction-services/publications/assets/functional-foods.pdf.
9. According to Jim Carroll, one of the world’s leading global future trends and
innovation experts, the sale of health and wellness oriented foods is expected to quadruple
throughout the next five years. Jim Carroll, The Big Food Industry Trend for 2012: Bold Goals,
Big Bets, JIM CARROLL BLOG (Nov. 11, 2011), http://www.jimcarroll.com/2011/11/the-big-
food-industry-trend-for-2012-bold-goals-big-bets/.
10. One such company is Ferrero, maker of the chocolate-hazelnut spread Nutella.
Ferrero was sued by two San Diego mothers for telling consumers that Nutella “is healthier
than it actually is.” NUTELLA CONSUMER CLASS ACTION SETTLEMENTS, https://nutellaclassac-
tionsettlement.com/Home.aspx (last updated Sept. 5, 2012). Ferrero settled the lawsuit for
a reported $3 million. Id.
11. In addition to POM Wonderful, Mr. and Mrs. Resnick also own Fiji Water,
Teleflora, Paramount Farming Company, and Paramount Citrus. The couple previously
owned the Franklin Mint Company but sold it in 2006. Amanda Fortini, Pomegranate Prin-
cess, NEW YORKER, Mar. 31, 2008, at 92, available at http://www.newyorker.com/reporting/
2008/03/31/080331fa_fact_fortini.
12. Opinion at 1, In re POM Wonderful LLC, No. 9344, (F.T.C. Jan. 10, 2013) [herein-
after POM II], available at http://ftc.gov/os/adjpro/d9344/130116pomopinion.pdf.
13. Id. Or, as Michael Hiltzik of the LA Times wrote, “[i]t has long been clear that the
most wonderful thing about POM Wonderful pomegranate juice is the spectacular market-
ing skill that persuades consumers to fork over their hard-earned cash for a liquid that sells
for five to six times the price of, oh, cranberry juice.” Michael Hiltzik, FTC Judge Calls Foul
on POM Pomegranate Marketing, L.A. TIMES (May 21, 2012), http://articles.latimes.com/
2012/may/21/news/la-mo-pom-20120521.
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aging, heart disease, stroke, Alzheimer’s, even cancer. Eight ounces a
day is all you need.”14
The FTC took POM to task for their claims by filing an adminis-
trative complaint against POM Wonderful in September 2010.15 The
FTC alleged that the company’s advertising was deceptive and in viola-
tion of the Federal Trade Commission Act (“FTC Act”).16 The FTC
Act prohibits “any false advertisement” that is intended or likely to
induce consumers to purchase food, drugs, devices, services, or cos-
metics,17 and declares the dissemination of such a false advertisement
an “unfair or deceptive act or practice.”18
In May 2010, Chief Administrative Law Judge (“ALJ”) D. Michael
Chappell agreed with the FTC and found that nineteen of the forty-
three challenged advertisements implicitly claimed that POM Juice,
POMx Liquid, and POMx Pills (collectively “Challenged POM Prod-
ucts”) could prevent, treat, cure, or mitigate heart disease, prostate
cancer, and erectile dysfunction.19 Since the ALJ’s decision was a par-
tial victory for both POM and the FTC, both sides appealed, which
necessitated a ruling from the FTC as a whole (“the Commission”).
On January 16, 2013, the Commission affirmed the ALJ’S initial deci-
sion.20 The Commission found that thirty-six of POM’s forty-three
claims were implied disease claims—claims that a product can diag-
nose, cure, mitigate, treat, or prevent disease21—seventeen more than
the ALJ had found.22
The POM case continues to be closely followed by the food indus-
try because it addresses the broader question: What does a company
need to do to adequately substantiate its product’s health benefits?23
The Commission, in its decision, imposed greater substantiation re-
14. Appendix to initial decision at 108, In re POM Wonderful LLC, No. 9344 (F.T.C.
May 17, 2012) [hereinafter POM Appendix], available at, http://www.ftc.gov/os/adjpro/
d9344/120521pomappendix.pdf.
15. See Complaint, In re POM Wonderful LLC, No. 9344 (F.T.C. Sept. 24, 2010),
[hereinafter POM Complaint], available at http://www.ftc.gov/os/adjpro/d9344/100927
admincmplt.pdf.
16. Id.; 15 U.S.C. §§ 41–58 (2006).
17. Id. § 52(a)(1)–(2).
18. Id. § 52(b).
19. POM Appendix, supra note 14 at 84–85.
20. POM II, supra note 12 at 3.
21. POM Appendix, supra note 14 at 21–34.
22. See POM II, supra note 12 at 9.
23. Elaine Watson, Will POM Wonderful Finally Clear Up Confusion Over What Evidence Is
Needed to Support Ad Claims?, FOOD NAVIGATOR-USA.COM (Dec. 7, 2012), http://www.food-
navigator-usa.com/Regulation/Will-POM-Wonderful-case-finally-clear-up-confusion-over-
what-evidence-is-needed-to-support-ad-claims.
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quirements than the historically flexible “competent and reliable sci-
entific evidence” standard.24 In order to meet the Commission’s
standard, a product’s disease-related efficacy claim now requires
double-blind, randomized well-controlled trials (“RCTs”).25 Widely
known as the gold standard of clinical trials,26 RCTs are commonly
used for drug testing.27 Because of the expense associated with RCTs,
critics of the Commission’s decision, such as the Alliance for Natural
Health USA, accused the FTC of gagging food manufacturers from
informing the public about their products’ health benefits, implicat-
ing the protections of the First Amendment.28 According to Washing-
ton food industry attorney Mark Mansour,29 the “FTC has drawn a
very specific and an exacting line in the sand that will impose serious
limitations and expensive, time-consuming, and unrealistic constraints
on the ability of food manufacturers to communicate to consumers
positive research developments about their products.”30
This Comment explores the recent proliferation of food health
claims. Part I outlines the current regulatory standard for food health
claims and discusses why its inadequacies harm both consumers and
businesses. Part II highlights the FTC’s recent efforts to regulate these
claims through voluntary consent agreements and the resulting back-
lash from companies challenging the FTC’s legal authority to regulate
in this manner. Part III discusses the key issues determined by In the
Matter of POM Wonderful,31 and its likely implications on the food and
supplement industry.
24. POM II, supra note 12 at 22.
25. Id.
26. Opinion at 108, In re POM Wonderful LLC, No. 9344 (F.T.C. May 17, 2012) [here-
inafter POM I], available at, http://www.ftc.gov/os/adjpro/d9344/120521pomdecision.
pdf.
27. Id. at 102–103.
28. The Alliance for Natural Health USA, FTC Proceeds with Raw Power Grab on Health
Claims—In Effect Thumbing Its Nose at Congress (Jan. 22, 2013), http://www.anh-usa.org/ftc-
proceeds-with-raw-power-grab-on-health-claims/. In the article, The Alliance for Natural
Health USA calls for the passing of the Free Speech about Science Act, which would allow
natural product companies, like POM, to cite peer-reviewed science in their advertising. Id.
29. For Mark Mansour’s professional profile, see Mark Mansour, AKIN GUMP, http://
www.akingump.com/en/lawyers-advisors/mark-mansour.html (last visited Apr. 15, 2013).
30. Alicia Mundy, FTC Bars Pom Juice’s Health Claims, WALL ST. J. (Jan. 16, 2013), http:/
/online.wsj.com/article/SB10001424127887323468604578245740405648024.html.
31. See POM II supra note 12; POM I supra note 26.
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I. Food has Fallen Through the Regulatory Cracks
The FTC’s truth-in-advertising law is comprised of two common-
sense propositions: (1) advertising must be truthful and not mislead-
ing;32 and (2) before disseminating an ad, advertisers must be able to
adequately substantiate all objective product claims.33
Although these requirements seem relatively simple, their execu-
tion in practice leaves much to be desired. The combination of mis-
matched regulations,34 arbitrary distinctions,35 and unclear
substantiation guidelines,36 means litigation will continue to define
the parameters of permissible health-related claims on a case-by-case
basis.37 Congress could fairly easily enact a law providing clear guide-
lines on the amount and type of evidence required to make a health
claim in a manner that is understood by consumers and backed by
good science.38 This cat and mouse game between the food industry
and government regulators is not in the best interest of either group,
and least of all, the consumer; but without congressional intervention
it will continue.39
A. FTC Jurisdiction Over Food Advertising
In 1914, Congress passed the FTC Act, creating the FTC, a fed-
eral agency with jurisdiction over economic competition and con-
sumer protection.40 “Prior to 1938, any authority the FTC possessed to
regulate food product claims was strictly implied” because the FTC
did not have express statutory authority to regulate food advertising.41
32. These principles are articulated in the FTC’s Policy Statements on Deception and
Advertising Substantiation. See FTC Policy Statement on Deception (Oct. 14, 1983), re-
printed in In re Cliffdale Assocs., Inc., 103 F.T.C. 110 app. at 174 (1984) [hereinafter FTC
Deception Statement], available at http://www.ftc.gov/bcp/policystmt/ad-decept.htm;
FTC Policy Statement Regarding Advertising Substantiation, reprinted in In re Thomas Med.
Co., 104 F.T.C. 648 app. at 839 (1984) [hereinafter FTC Advertising Statement], available
at http://www.ftc.gov/bcp/guides/ad3subst.htm.
33. See FTC Advertising Statement, supra note 32.
34. See infra Part I.B.
35. See infra Part I.C.
36. See infra Part I.D.
37. See Jann Bellamy, POM: Not So Wonderful, SCIENCE-BASED MED. (May 31, 2012),
http://www.sciencebasedmedicine.org/index.php/pom-not-so-wonderful/.
38. Id.
39. Id.
40. See Federal Trade Commission Act, Pub. L. No. 63–203, § 1, 38 Stat. 717 (1914)
(codified as amended at 15 U.S.C. §§ 41–58 (2006)) (establishing the FTC).
41. Chelsea M. Childs, Note, Federal Regulation of the “Smart Choices Program”: Subjecting
Front-of-Package Nutrition Labeling Schemes to Concurrent Regulation by the FDA and the FTC, 90
B.U. L. REV. 2403, 2410 (2010) (citing 15 U.S.C. §§ 41–77 (2006)).
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In 1938, Congress passed the Wheeler-Lea Amendments, giving the
FTC express jurisdiction over all food advertising.42 These amend-
ments outlawed “deceptive acts or practices in commerce” and em-
powered the FTC to prevent such acts or practices.43 The FTC Act
now prohibits “any false advertisement” that is intended or likely to
induce consumers to purchase food,44 and declares the dissemination
of such a false advertisement an “unfair or deceptive act or practice.”45
As discussed in more detail below,46 the FTC may enforce the
FTC Act through rulemaking, which affects an entire industry,47 or
adjudication, which issues a case-specific decision with respect to an
individual advertiser’s practices.48 Section twelve of the FTC Act gives
the FTC authority to institute administrative cease and desist order
proceedings against persons whom the FTC believes are disseminating
advertisements in violation of section twelve.49 Thus, when the FTC
believes that a claim is false or misleading, it typically orders the adver-
tiser to cease and desist from making such claims.50
After the FTC issues a cease and desist order, it usually “proceeds
with the customary administrative hearing and [FTC] determination,
followed by the opportunity for court appeal.”51 The administrative
hearing focuses on whether the advertiser’s claim is deceptive.52 “A
deceptive claim is one that ‘is false and misleading in itself’ or ‘lacks
substantiation,’ and therefore violates the FTC Act.”53 Whether a
42. Wheeler-Lea Amendments of 1938, Pub. L. 75–447, § 4, 52 Stat. 111, 114–17
(1938) (codified as amended at 15 U.S.C. § 45).
43. Id. § 3, 52 Stat. 111–12.
44. 15 U.S.C. § 52(a)(1)–(2).
45. Id. § 52(b).
46. See infra Part II.A.
47. See 15 U.S.C. § 57(a)(1)(B).
48. See id. § 45(b).
49. Id.
50. Id. In deciding whether to commence an action against an advertiser, the FTC
considers several factors, including: (1) whether the FTC has jurisdiction over advertise-
ments made about the product in question; (2) whether the advertising campaign is na-
tional in geographic scope; (3) whether the advertisement “represents a pattern of
deception, rather than an individual dispute between a consumer and a business or a dis-
pute between two competitors;” and (4) the extent to which the advertisement harmed
consumer health, safety, or finances. FED. TRADE COMM’N, ADVERTISING PRACTICES: FRE-
QUENTLY ASKED QUESTIONS, ANSWERS FOR SMALL BUSINESS 7 (2001), available at http://busi-
ness.ftc.gov/sites/default/files/pdf/bus35-advertising-faqs-guide-small-business.pdf
(responding to the question: “How does the FTC decide what cases to bring?”).
51. Childs, supra note 41, at 2409.
52. Id.
53. Id.
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claim is deceptive requires the resolution of three factors.54 First, the
FTC considers whether the advertiser uses a “a representation, omis-
sion, or practice that is likely to mislead the consumer.”55 The chal-
lenged claim may constitute an express claim such as “this product
reduces the risk of heart disease,” an implied claim such as “pome-
granate reduces the risk of heart disease; this product contains pome-
granate,” or an omission.56
Second, the FTC considers whether the representation is likely to
mislead the reasonable consumer.57 The FTC judges consumer rea-
sonableness in light of the advertisement’s target audience.58
Third, the representation must be material in that it is “likely to
affect a consumer’s conduct or decision with regard to a product.”59 A
representation is presumed material when the advertiser makes an ex-
press claim, intends to make an implied claim, omits information that
it knew or should have known a consumer requires, or makes a claim
involving health or safety.60
[T]he FTC will not consider an advertiser’s claim deceptive under
two circumstances. First, despite literally false claims, an advertise-
ment is “not legally deceptive if consumers understand that the
claims are not meant to be taken literally, and therefore are not
misled into forming false beliefs.” For example, “[t]he claim that
‘Exxon puts a tiger in your tank,’ though literally false, is not le-
gally actionable.” Second, an advertisement is not deceptive if the
advertiser has adequate substantiation for any claims regarding its
products. “The FTC balances six factors in determining the appro-
priate level of substantiation required for an advertised product:
(1) the nature of the product involved, (2) the type of claim, (3)
the benefits of a truthful claim, (4) the cost of developing substan-
tiation for the claim, (5) the consequences of a false claim, and (6)
the amount of substantiation that reasonable experts in the field
would agree on.”61
54. Id. (internal citations omitted).
55. FTC Deception Statement, supra note 32, at 175.
56. See Childs, supra note 41, at 2409. With respect to an implied claim, identifying the
exact claim made by an advertiser is often difficult and controversial. Id. The FTC has the
authority to “rely on its reasoned analysis to determine what claims, including implied
ones, are conveyed in a challenged advertisement, so long as those claims are reasonably
clear from the face of the advertisement.” Id. (citing Kraft, Inc. v. FTC, 970 F.2d 311, 319
(7th Cir. 1992)).
57. FTC Deception Statement, supra note 32, at 175.
58. Id.
59. Id.
60. Id.
61. See Childs, supra note 41, at 2410 (internal citations omitted).
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When it comes to food advertising, however, the FTC must often
seek the opinion of outside parties such as the Food and Drug Admin-
istration (“FDA”) to complete its deceptive advertising analysis.62
B. The FTC and FDA: Complementary Regulation
Pursuant to the regulatory scheme established by Congress
through complementary statutes, the FTC and FDA operate under a
Memorandum of Understanding63 that governs the division of respon-
sibilities between the two agencies over claims by food manufactur-
ers.64 The current understanding is that the FTC has jurisdiction over
food advertising and the FDA has jurisdiction over food labeling.65
In response to the Nutrition Labeling and Education Act of 1990
(“NLEA”),66 which required FDA regulation of disease-prevention
claims in food labeling,67 the FTC issued the Enforcement Policy
Statement on Food Advertising in 1994.68 Although the NLEA applies
only to food labeling, the FTC recognized the importance of the con-
sistent treatment of health claims in both food advertising and label-
62. See, e.g., infra note 66.
63. Memorandum of Understanding Between the Federal Trade Commission and the
Food and Drug Administration, 36 Fed. Reg. 18,539, 18,539 (Sept. 16, 1971) (replacing
and updating previous agreements between the FTC and FDA) [hereinafter FTC/FDA
MoU]. The FTC/FDA MoU states the division as follows:
In order to facilitate the purposes of this agreement, it is specifically agreed that:
With the exception of prescription drugs, the Federal Trade Commission has pri-
mary responsibility with respect to the regulation of the truth or falsity of all ad-
vertising (other than labeling) of foods, drugs, devices, and cosmetics. In the
absence of express agreement between the two agencies to the contrary, the Com-
mission will exercise primary jurisdiction over all matters regulating the truth or
falsity of advertising of foods, drugs, . . . devices, and cosmetics;
The Food and Drug Administration has primary responsibility for preventing mis-
branding of foods, drugs, devices, and cosmetics shipped in interstate com-
merce. . . . In the absence of express agreement between the two agencies to the
contrary, the Food and Drug Administration will exercise primary jurisdiction
over all matters regulating the labeling of foods, drugs, devices, and cosmetics.
Id.
64. The FDA’s food labeling authority is embodied in Section 403(a) of the FDCA,
which prohibits false or misleading advertising. Food, Drug and Cosmetic Act, Pub. L. No
75-717, § 403(a), 52 Stat. 1040, 1047 (1938).
65. See generally FTC/FDA MoU, supra note 63.
66. Nutrition Labeling and Education Act of 1990, Pub. L. No. 101-535, 104 Stat. 2353
(codified as amended in scattered sections of 21 U.S.C.).
67. Id. The NLEA amended Section 403 of the FDCA and requires nutrition informa-
tion on virtually all food products, directs the FDA to standardize and limit the terms per-
mitted on labels, and allows only FDA-approved nutrient content claims and health claims
to appear on food labels. See id.
68. FTC Enforcement Policy Statement on Food Advertising, 59 Fed. Reg. 28,388
(June 1, 1994).
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ing.69 Thus, the FTC will generally look to the FDA’s labeling
regulations in evaluating health claims made in food advertising, ac-
knowledging the FDA’s specific scientific expertise.70
Critics of this approach cite the fundamental differences that ex-
ist between the two agency’s regulatory schemes.71 Congress has long
recognized the division of roles between the two agencies—the FTC
concentrates on the interests of commerce and economic needs,
whereas the objective of the FDA is the “health of the people.”72 The
sphere of regulation of food health claims, however, is one in which
the traditional mandates of the two agencies are seemingly
intertwined.73
C. Health Claims: Terms of Art
There are several types of nutrition and health claims commonly
associated with food products, including health claims, structure/
function claims, and dietary guidance statements. Health claims sug-
gest a link between consuming a food and reducing the risk of “a dis-
ease or a certain health-related condition.”74 The statement “[d]iets
69. Id.
70. Id. Although similar, the regulation standards of the FTC and FDA are not
identical:
While the Commission’s approach to evaluation of unqualified health claims will
generally parallel FDA’s assessment of whether there is significant scientific agree-
ment supporting the relevant diet-disease relationship, the Commission recog-
nizes that there may be certain limited instances in which carefully qualified
health claims may be permitted under section 5 although not yet authorized by
the FDA, if the claims are expressly qualified to convey clearly and fully the extent
of the scientific support.
Id. at 28,394.
71. Before the passage of the Wheeler-Lea Amendments of 1938, congressional mem-
bers were divided amongst those who supported FTC jurisdiction over food advertising and
those who believed that the FDA should have advertising jurisdiction. “Those supporting
extending the FDA’s jurisdiction over advertising argued that the FTC was concerned pri-
marily with economic issues, such as trade and competition, and not the protection of
consumer health, and that advertising regulation is a necessary corollary to labeling regula-
tion.” Nicole Gerhart, The FDA & the FTC: An Alphabet Soup Regulating the Misbranding
of Food 3 (Apr. 30, 2002) (unpublished course paper, Food and Drug Law, Winter 2001),
http://dash.harvard.edu/bitstream/handle/1/8965563/Gerhart.html?sequence=2.
72. General Requirements for Health Claims for Dietary Supplements, 55 Fed. Reg.
395, 405 (1994) (internal quotations omitted).
73. See infra Part I.C.
74. Barbara O. Schneeman, U.S. Food & Drug Admin., Guidance for Industry and
FDA: Dear Manufacturer Letter Regarding Food Labeling (Jan. 2007), http://www.fda.
gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/Labeling
Nutrition/ucm053425.htm [hereinafter Dear Manufacturer Letter] (citing 21 C.F.R.
§ 101.14 (2009)).
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low in sodium may reduce the risk of high blood pressure” is an exam-
ple of a health claim.75 Structure/function claims are similar to health
claims, but instead of describing a relationship between consumption
of a certain food and a health condition or disease, they describe how
consumption affects the normal structure or function of the human
body.76 For example, “calcium builds strong bones” is a structure/
function claim because it cites a specific effect—bone strength—as
the result of consuming a certain nutrient, calcium.77 Dietary gui-
dance statements, such as “[c]arrots are good for your health,” typi-
cally make broad, general health recommendations.78
The distinction amongst claims is critical because the amount of
substantiation required depends on whether a claim is characterized
as a health claim, structure/function claim or dietary guidance state-
ment. Neither structure/function claims nor dietary guidance state-
ments require FDA review or authorization before manufacturers may
use them in a label, as long as the statements are true and not mislead-
ing.79 The same is not true for health claims.80 Without increased sub-
stantiation, or prior FDA approval for labeling, a food product like
yogurt can claim to “regulate digestion,” so long as it doesn’t claim to
“treat chronic constipation.”81 Consumers are being flooded with un-
substantiated health claims, murkily disguised as structure/function
claims.82
D. Substantiation: Science Through Compliance
In its Enforcement Policy Statement on Food Advertising, the
FTC announced that it would examine health claims on a case-by-case
basis.83 Unlike the FDA, there is no pre-clearance of advertising claims
by the FTC, even if the advertisement is categorized as a health
claim.84 Instead, the FTC requires that an advertiser have a reasonable
basis to substantiate its claim from the time the claim is first made.85
The FTC’s substantiation standard is a flexible one, requiring that
75. Id.
76. Id. (citing 21 C.F.R. § 101.93).
77. Id.
78. Id.
79. See Dear Manufacturer Letter, supra note 74.
80. Id.
81. Herper & Ruiz, supra note 3.
82. See id.
83. FTC Enforcement Policy Statement on Food Advertising, 59 Fed. Reg. 28,388
(June 1, 1994).
84. Gerhart, supra note 71.
85. Id.
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claims be supported by “competent and reliable scientific evidence.”86
The FTC has interpreted this requirement to mean: “[T]ests, analyses,
research, studies or other evidence based on the expertise of profes-
sionals in the relevant area, that have been conducted and evaluated
in an objective manner by persons qualified to do so, using proce-
dures generally accepted in the profession to yield accurate and relia-
ble results.”87
The reason for this flexible standard is twofold: First, to ensure
that consumers have access to information about emerging areas of
science; and second, to maintain consumer confidence in the accu-
racy of information presented in advertising.88 Thus, there is no fixed
formula for the amount or type of study required, or for more specific
parameters like sample size and study duration. This case-by-case regu-
latory standard is inadequate and bad for both consumers and
companies.
Most consumers are not in a position to critically evaluate the
differences in credibility between small-scale manufactured studies
and large double-blind, placebo-controlled studies.89 Advertisers are
permitted to tout their products’ health-enhancing benefits based on
individual, manufacturer-sponsored studies,90 which increases the
likelihood that consumers will be misled. Essentially, these companies
get the best medical research outcome that money can buy,91 regard-
less of whether the underlying studies are flawed.92
86. 59 Fed. Reg. at 28,388.
87. Id.
88. See id. at 28,396. (“[W]hile the Commission recognizes the desirability of educat-
ing consumers about the role of other factors that bear on the risk of disease and how such
factors interact with diet, the Commission must evaluate whether the failure to disclose
such qualifying information in a claim about the health effects of a food would mislead
consumers.”).
89. David Vinjamuri, POM Wonderful’s Deception is the Tip of the Iceberg, FORBES (May 23,
2012), http://www.forbes.com/sites/davidvinjamuri/2012/05/23/judge-finds-pom-won-
derful-advertising-deceptive-but-thats-just-the-tip-of-the-iceberg/.
90. Id.
91. For example, in its advertisements, POM claimed to have invested more than $35
million in research to prove that pomegranate juice has health benefits. POM I, supra note
26, at 295.
92. For example, one POM study on the effects of drinking pomegranate juice on
myocardial perfusion, or blood flow to the heart, was conducted by Dr. Dean Ornish, a
Clinical Professor of Medicine at the University of California at San Francisco and the
Founder and President of the Preventative Medicine Research Institute in Sausalito, Cali-
fornia. The study was originally designed to last 12 months, however, the FTC charged that
the study was cut short when the three-month data came in favorably and Dr. Ornish faced
cost overruns. Dr. Frank Sacks, an expert witness for the FTC, stated that the shortened
study period and failure to report the planned duration were inconsistent with widely ac-
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Why are misled and increasingly skeptical consumers bad for
business?
Faced with a barrage of sensational claims relating to everything
from weight loss to impotence, we lose a measure of trust in all
brands. This loss of goodwill effectively becomes a tax born by ethi-
cal brands as well as dodgy ones, as gaining consumer trust and
loyalty becomes more difficult and more expensive for all.93
While the FTC and FDA have the enforcement power to stop
false and misleading claims, both agencies are subjected to continu-
ous budget pressure, and in practice, only the most egregious offend-
ers are addressed.94 For this reason, the FTC is seeking voluntary
compliance from offending businesses through consent orders.95 The
FTC’s ability to regulate through these voluntary consent orders, how-
ever, is being challenged.96
II. Voluntary Consent Orders: Regulation in the Twenty-First
Century?
The litigation between the FTC and POM began in September
2010 when POM filed an action in the District Court for the District of
Columbia, seeking a declaratory judgment against the FTC.97 To give
some background, in July 2010, the FTC entered into voluntary con-
sent agreements with two companies, Nestle´ Health Care Nutrition
and Iovate Health Sciences USA, whose advertisements were deemed
to overstate their products’ effect on disease prevention and mitiga-
tion by the FTC.98 Both agreements required the companies to root
their future health claims in “competent and reliable scientific evi-
dence . . . consist[ing] of at least two adequate and well controlled
cepted standards for conduct of clinical trials and undermine any confidence in the stand-
ings. In response, Dr. Ornish testified that the study was cut short only because the
Resnicks did not provide the funding that they had previously committed to. POM I, supra
note 26 at 268–69.
93. Vinjamuri, supra note 89.
94. Id.
95. “A company that signs a consent order need not admit that it violated the law, but
it must agree to stop the disputed practices outlined in an accompanying complaint.” Con-
sumer Protection: Law Enforcement, FED. TRADE COMM’N (July 27, 2007), http://www.ftc.gov/
bcp/menus/resources/enforcement.shtm.
96. See discussion infra Part II.B.
97. POM Wonderful LLC v. FTC, No. 10–1539 (RWR), 2012 WL 4475698 (D.D.C.
Sept. 30, 2012).
98. Id.; see also FTC v. Iovate Health Scis. USA, Inc., No. 10–cv–587 (W.D.N.Y. July 29,
2010), available at http://www.ftc.gov/os/caselist/0723187/100729iovatestip.pdf; Agree-
ment Containing Consent Order, Nestle´ HealthCare Nutrition, Inc., No. 092–3087, 2010
WL 2811203, at *10 (F.T.C. July 14, 2010).
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human clinical studies of the product.”99 The Nestle´ agreement also
provided that all disease-based representations be pre-approved by the
FDA.100
In its complaint, POM alleged that the FTC had enacted new and
obligatory advertising standards, including heightened standards for
scientific studies and prior FDA approval for all health claims, by pub-
lishing the Nestle´ and Iovate consent orders and insisting the orders
had the force of law.101 POM sought judgment that these purported
new rules governing disease claims in food advertising exceeded the
FTC’s statutory authority, violated POM’s First and Fifth Amendment
rights, violated the rulemaking procedures of the FTC and the Admin-
istrative Procedures Act (“APA”),102 and were arbitrary and
capricious.103
A. Notice-and-Comment Rulemaking Versus Voluntary Consent
Orders
The FTC promulgates broad policies in accordance with the ad-
ministrative law concept of “rulemaking”. In National Petroleum Refiners
Association v. FTC,104 the District of Columbia Court of Appeals upheld
the agency’s authority to make legislative rules, those that have the
force of law through the informal procedures of section 553 of the
APA. Notice-and-comment rulemaking (otherwise known as informal
rulemaking) is a common rulemaking procedure under which a pro-
posed agency rule is published in the Federal Register and is open to
comment by the general public.105
Section 553 provides that legislative rules should be made after
publishing notice in the Federal Register, giving opportunity for written
99. See Iovate, No. 10–cv–587, at 7; Nestle´, No. 092–3087, at *4.
100. Nestle´, No. 092–3087, at *3.
101. Complaint for Declaratory Relief at 6, POM Wonderful LLC v. FTC, No.
10–01539, 2010 WL 3968871 (D.D.C. Sept. 13, 2010).
102. Administrative Procedure Act (APA) of 1946, 5 U.S.C. §§ 500–559 (2006).
103. POM Wonderful LLC, No. 10-1539 (RWR), 2012 WL 4475698, at *41.
104. 482 F.2d 672 (D.D.C. 1973).
105. 5 U.S.C. § 553. The APA, however, has carved out a number of exceptions to the
procedural informal rulemaking requirements. For example, all rules pertaining to (1) “a
military or foreign affairs function of the United Stares,” (2) “a matter relating to agency
management or personnel,” or (3) a matter relating to “public property, loans, grants,
benefits, or contracts” are wholly exempt. 5 U.S.C. § 553(a). The APA also provides an
exception to the notice-and-comment rulemaking procedure for “ interpretative rules,
general statements of policy, and rules of agency organization, procedure, or practice.” Id.
§ 553(b)(A).
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comments, and providing a statement of support for the rules.106 The
final rule must be published in the Federal Register not less than thirty
days before the rule’s effective date.107 Many commentators feel that
notice-and-comment rulemaking, is an effective and equitable mecha-
nism.108 Despite its general efficacy, business interest groups have reg-
ularly criticized the FTC’s legislative rulemaking activities.109
Consequently, the FTC also seeks compliance from offending
companies through individual consent orders. Generally, the FTC be-
gins investigating a company it believes is making dubious or exagger-
ated claims. For example, the FTC’s consent agreement with Nestle´
regarding the company’s BOOST Kid Essentials drink.110 If the results
of the investigation reveal unlawful conduct, the FTC may seek volun-
tary compliance by the offending company through a consent order
in lieu of filing an administrative complaint.111 Since the agreement is
private, it may contain any measure agreed upon, regardless of what is
considered common practice in the industry.
In effect, consent decrees allow the FTC to effectively (and extra-
judiciously) regulate offending companies, while companies are
spared the immediate costs and consequences of litigation. The prac-
tice, however, may have industry-wide impact, as the FTC is accused of
using consent orders to leverage other companies, like POM, into
greater compliance.112
B. POM Wonderful, LLC v. FTC
In its federal complaint, POM alleged that the FTC specifically
advised POM that it was applying a new standard of review for decep-
tive advertising based on the Nestle´ and Iovate consent orders.113 Ac-
cording to this new standard, advertisers were required to: (1) obtain
prior FDA approval before making certain types of health claims, spe-
cifically disease claims; and (2) conduct two well-controlled clinical
106. Charles Koch & Beth Martin, FTC Rulemaking Through Negotiation, 61 N.C. L. REV.
275, 279 (1983).
107. 5 U.S.C. § 552(d)(1).
108. Koch & Martin, supra note 106, at 280.
109. Id.
110. See, e.g., Agreement Containing Consent Order, Nestle´ HealthCare Nutrition,
Inc., No. 092–3087, 2010 WL 2811203 (F.T.C. July 14, 2010).
111. See, e.g., id.
112. See infra Part II.B.
113. Complaint for Declaratory Relief at 6, POM Wonderful LLC v. FTC, No.
10–01539, 2010 WL 3968871 (D.D.C. Sept. 13, 2010).
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studies for non-disease claims.114 POM alleged that these new stan-
dards were “not merely interpret[ive of] present standards or rules,”
but rather were directly contrary to “over twenty . . . years of FTC food
advertising rules and regulations.”115
POM believed that the FTC violated the APA by implementing a
new rule requiring RCTs without notice-and-comment rulemaking.116
POM also alleged that the FTC had never before “require[d] prior
FDA approval” irrespective of whether the claims “are true or sup-
ported by competent, reliable scientific evidence[.]”117 According to
POM, by requiring prior FDA approval regardless of whether the
claims are true or supported by competent and reliable scientific evi-
dence, the FTC was seeking to restrain non-deceptive speech, in viola-
tion of the First Amendment and the FTC’s statutory authority.118
Shortly after POM filed its action for declaratory relief, the FTC
filed an administrative complaint against POM.119 In September 2012,
the district court declined to exercise its discretionary jurisdiction
under the Declaratory Judgment Act and dismissed POM’s suit due to
the pending overlapping proceeding.120
III. In the Matter of POM (Not So) Wonderful
Two weeks after POM filed its claim against the FTC in federal
court, the FTC filed an administrative complaint against POM.121 The
FTC alleged that POM engaged in deceptive acts and disseminated
false advertising in violation of sections 5(a) and 12 of the FTC Act.122
114. POM Wonderful LLC v. FTC, No. 10-1539 (RWR), 2012 WL 4475698, at *1
(D.D.C. Sept. 30, 2012).
115. Id.
116. Id.
117. Id.
118. Id. at *2.
119. Id.
120. POM Wonderful Sept. 30, 2012, supra note 114, at *2. In dismissing the suit, the
court noted that “[g]enerally, in the interest of judicial efficiency, courts decline to hear
declaratory judgment actions that would not fully resolve the parties’ claims. Here, if the
court resolved the issues POM raised in its declaratory judgment action, the parties would
still have to litigate whether POM’s health claims about its products were false, misleading,
and unsubstantiated in violation of the FTC Act.” Id. The court further stated that the
Commission hearing “is ‘perfectly capable’ of determining whether the proposed order
exceeds the bounds of the FTC Act, violates the First and Fifth Amendments, and seeks to
abrogate the FDA’s power.” Id. at *3 (citation omitted).
121. See POM Complaint, supra note 15.
122. Id. As previously discussed, Section 5(a) of the FTC Act provides that “unfair or
deceptive acts or practices in or affecting commerce are hereby declared unlawful.” 15
U.S.C. § 45(a)(1) (2006). Section 12 of the FTC Act prohibits the dissemination of “any
false advertisement” in order to induce the purchase of “food, drugs, devices, services, or
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The FTC challenged forty-three POM advertisements and promo-
tional pieces, including print advertisements, newsletters, website ad-
vertisements, and “public relations” promotional materials.123
Specifically, the FTC alleged that POM’s ads represented that the
daily consumption of the Challenged POM Products will “treat, pre-
vent, or reduce the risk of heart disease . . . prostate cancer . . . [or]
erectile dysfunction,” without having a reasonable basis to substantiate
such claims.124 Additionally, POM’s ads claimed “clinical studies, re-
search, and/or trials prove that consuming the POM Products ‘pre-
vents or reduces the risk of’ or ‘treats’ heart disease, prostate cancer
or erectile dysfunction,”125 when in fact clinical studies, research, or
trials did not so prove.126 The FTC proposed that POM agree to pre-
screening by the FDA of any claims that its products cure, prevent,
treat, or reduce the risk of any disease to prevent future violations.127
The FTC also demanded that POM refrain from making any other
health-related claims about its products without “competent and relia-
ble scientific evidence” from two RCTs.128
In determining whether POM disseminated false or misleading
advertisements, the ALJ and Commission used the following three-
part inquiry: “(1) whether [POM] disseminated advertisements con-
veying the claims alleged in the Complaint; (2) whether those claims
were false or misleading; and (3) whether those claims are material to
prospective consumers.”129
A. Step One: Identifying Claims and Interpreting Ad Meaning
The first step in evaluating the truthfulness and accuracy of ad-
vertising is identifying all express and implied claims that an ad con-
veys to consumers.130 Although advertisers must ensure that whatever
is expressly claimed in an ad is accurate, an advertiser is equally re-
cosmetics.” Id. § 52(a)(2). For the purposes of Section 12, “false advertisement” is defined
as “an advertisement, other than labeling, which is misleading in a material respect.” Id.
§ 55(a).
123. POM I, supra note 26, at 207.
124. POM Complaint, supra note 15, at 16–19.
125. Id. at 16–17.
126. Id.
127. Id. at 22.
128. Id.
129. POM I, supra note 26, at 211.
130. FTC Deception Statement, supra note 32, at 175.
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sponsible for the accuracy of claims suggested or implied.131 Thus,
advertisers cannot suggest claims that they could not make directly,
through, for example, the juxtaposition of phrases and images.
In their complaint, the FTC believed that POM’s advertisements
claimed daily consumption of Challenged POM Products “treats, pre-
vents or reduces the risk of heart disease, prostate cancer, or erectile
dysfunction.”132 Claims that a product is effective without expressly or
impliedly representing a level of support are called “efficacy
claims.”133 According to the FTC, POM falsely represented that it pos-
sessed and relied upon a reasonable basis for substantiating its efficacy
claims.134 Consequently, the representations were false or
misleading.135
POM also represented that “clinical studies, research, and/or tri-
als prove” that drinking POM Juice or taking POMx Pills or Liquid
daily treats the diseases or prevents or reduces the risk of each of the
diseases.136 Such claims are referred to as “establishment claims”—
expressly or clearly implied statements that the advertising claim is
supported by scientific or medical studies.137 Common examples of
establishment claims include statements such as “tests prove,” “studies
show,” or “doctors recommend.”138
The ALJ found that nineteen of the forty-three challenged ads
and promotional materials conveyed health claims, but the Commis-
sion believed that the actual number was thirty-six.139
Because none of the ads expressly stated that the Challenged
POM Products “treat, prevent, or reduce the risk of heart disease,
prostate cancer, or erectile dysfunction,” the Commission relied on
the ads’ implicit messages. Declining to focus solely on the individual
phrases or statements in the ads—many of which were humorous or
irreverent like the “Cheat Death” slogan—the Commission consid-
ered the individual ads as a whole.140 Assessing the “net impression” of
131. FED. TRADE COMM’N, BUREAU OF CONSUMER PROTECTION, DIETARY SUPPLEMENTS:
AN ADVERTISING GUIDE FOR INDUSTRY (2001), available at http://business.ftc.gov/sites/de-
fault/files/pdf/bus09-dietary-supplements-advertising-guide-industry.pdf.
132. See POM Complaint, supra note 15, ¶¶ 9–10, 19.
133. POM II, supra note 12, at 7.
134. Id. at 18.
135. Id.
136. Id. (citing POM Complaint, supra note 15, ¶¶ 9–10, 12, 14, 16).
137. FTC Advertising Statement, supra note 32, at 194 (“Advertisements that claim a
certain type or level of support are considered establishment claims.”).
138. Id.
139. POM II, supra note 12, at 9.
140. Id. at 9–12.
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the ads through words and images, both the ALJ and Commission
found that certain ads made health claims indirectly through logical
syllogism.141 For instance: “free radicals cause or contribute to heart
disease; the POM Products contain antioxidants that neutralize free
radicals; therefore, the POM Products are effective for heart
disease.”142
As to the establishment claims, the Commission found that
POM’s textual representations (i.e., “eight ounces a day can reduce
plaque by up to 30%!”) that specified scientific support (i.e., “[b]ased
on a clinical study”) conveyed the existence of clinical proof for the
disease claims made, regardless of the small print and qualified asser-
tion.143 Furthermore, the Commission noted that statements relating
to the millions of dollars spent on medical research reinforced the
impression that the research supporting the claims was established
and not merely preliminary.144
B. Step Two: False and Deceptive or Substantiated
Since thirty-six ads implied that the Challenged POM Products
provided a disease benefit, the next question was whether POM could
adequately substantiate its health claims. Because POM lacked ade-
quate substantiation, its claims were deemed false (as to the establish-
ment claims) and lacking a reasonable basis (as to the efficacy
claims).145
1. POM’s False Establishment Claims.
The FTC alleged, and the Commission agreed, that POM’s estab-
lishment claims were false.146 The company did not possess a level of
proof sufficient to satisfy the relevant scientific community of the
claim’s truth, specifically that the Challenged POM Products treat,
prevent, or reduce the risk of heart disease, prostate cancer, or erec-
141. POM I, supra note 26, at 225.
142. Id.
143. POM II, supra note 12, at 13. The Commission noted:
The specific percentage reduction of plaque in someone’s arteries cannot be as-
certained by any means other than by scientific measurement, and the statement
therefore implies that the claim of plaque reduction is scientifically established.
The claim of scientific proof is bolstered by the asterisk that directs the reader to
the quoted citation for the ‘clinical pilot study,’ which the Commission acknowl-
edges is in small print.
Id.
144. Id. at 14.
145. Id. at 34, 38.
146. Id. at 12–14.
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tile dysfunction.147 In order to determine the standards that the rele-
vant scientific and medical communities would demand, the
Commission reviewed the testimony of the fourteen expert witnesses
qualified in the fields of heart disease, prostate cancer, and erectile
dysfunction who were called as witnesses by the FTC and POM before
the ALJ.148
Based on a review of the entire record, including 2000 exhibits
and a 3300 page transcript, the Commission concluded that: (1)
POM’s establishment claims were not adequately substantiated; and
(2) a higher level of substantiation would be necessary to support
POM’s establishment claims.149 The ALJ determined that experts in
the relevant fields would require “competent and reliable evidence
[that] must include clinical studies although not necessarily RCTs” to
support POM’s claims.150 In contrast, the Commission found that ex-
perts required RCTs to establish a causal relationship between food
and the treatment, prevention, or reduction of the risk of heart dis-
ease, prostate cancer, or erectile dysfunction.151
2. POM’s Efficacy Claims Lacked a Reasonable Basis.
The FTC alleged that POM lacked a “reasonable basis” for its effi-
cacy claims.152 “[A]n objective claim about a product’s performance
or efficacy carries with it an express or implied representation that the
advertiser had a reasonable basis of support for the claim.”153 In deter-
mining what constitutes a reasonable basis, the FTC generally consid-
ers the “Pfizer factors,” factors relevant to the benefit and costs of
substantiating a claim.154
147. Id.
148. Id. at 22.
149. POM II, supra note 12, at 22.
150. POM I, supra note 26, at 253.
151. POM II, supra note 12, at 23. The Commission found “that RCTs are required to
substantiate [POM’s] disease claims because it is necessary to isolate the effect of consum-
ing the Challenged POM Products on the incidence of the disease, and the expert testi-
mony revealed that only RCTs can isolate that effect.” Id.
152. Id. at 17.
153. Id. (citing Thompson Med. Co., 104 F.T.C. 648.813 (1984)) “Consumers find
these representations of support to be important in evaluating the reliability of the product
claims. Therefore, injury is likely if the advertisement lacks support for the claims.” Id.
154. Id. at 18; FTC Advertising Statement, supra note 32, at 840 (explaining that the
“determination of what constitutes a reasonable basis depends . . . on a number of factors
relevant to the benefits and costs of substantiating a particular claim . . . [including,] the
type of claim, the product, the consequences of a false claim, the benefits of a truthful
claim, the cost of developing substantiation for the claim, and the amount of substantia-
tion experts in the field believe is reasonable”).
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The experts called by both the FTC and POM consistently testi-
fied that the degree of substantiation necessary for general nutritional
and health benefits claims is different than the requisite level of sub-
stantiation for specific disease treatment and prevention claims.155
Thus, according to one POM expert, “the standard of substantiation is
different for a product that is directly associated as a treatment for
erectile dysfunction and for a product that claims to have helpful ben-
efits for or improves one’s erectile function.”156
After the Commission found that the efficacy claims made by
POM were related to disease treatment and prevention, it declined to
determine the requisite level of substantiation for generalized nutri-
tional and health claims involving food products.157 POM argued that
pomegranate juice’s categorization as a non-hazardous food158 should
exempt POM from the RCT requirement because such studies are im-
practical, impossible, unethical, and too costly.159 This argument was
rejected.160 Focusing on the nature of the claims made—disease
claims—rather than the nature of the product making the claim—all-
natural pomegranate juice—the Commission determined that RCTs
were required to substantiate POM’s efficacy claims.161
C. Step Three: POM’s Claims Were Material
A misleading claim in advertising only violates the FTC Act if the
misleading information is a material factor in the consumer’s decision
to purchase the product.162 A “material misrepresentation” is one that
is likely to affect a consumer’s conduct with respect to the product or
service.163 “Express claims, claims significantly involving health or
safety, and claims pertaining to the central characteristic of the prod-
155. POM II, supra note 12, at 20. Expert Dr. Stamper explained that if the claim does
not imply a causal link, then evidence short of RCTs would support the claim. Id. Even if a
product is safe and might create a benefit, like a fruit juice, he would still require an RCT
to justify claims that POM was charged with making. Id.
156. Id.
157. Id. at 20–21.
158. The FDA maintains a list of substances that it identifies as “Generally Regarded As
Safe” (“GRAS”). POM I, supra note 26, at 14. Before a substance can be GRAS identified,
the FDA reviews the scientific literature and the traditional consumption of the substance.
Both pomegranate juice and pomegranate extract are GRAS identified. Id.
159. POM II, supra note 12, at 24–25.
160. Id.
161. Id. at 22.
162. In re Am. Home Prods. Corp., 98 F.T.C. 136, 368 (1981).
163. FTC Deception Statement, supra note 32, at 182.
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uct,” are presumptively material.164 Consequently, because the claims
made by POM in the challenged advertisements were health-related
claims, they were presumptively material.165
POM argued that the claims were immaterial because they re-
lated to the health benefits of the Challenged POM Products, as op-
posed to claiming to prevent disease.166 The ALJ and the Commission
disagreed.167 Noting that the focus of the ads was not the Challenged
POM Products’ “taste, price, or other attributes, but rather their im-
pact on heart disease, prostate cancer or ED(erectile dysfunction),”
the Commission concluded that POM[‘s] “products’ impact on health
was such a strong selling point that they invested over $35 million to
develop supporting evidence that they could use in marketing.”168
The evidence indicated that POM was aware that sales increased when
the results of POM health studies were advertised.169 The Commission
determined that it was ‘“no great leap’ to find that consumer purchas-
ing decisions would likely be influenced by claims that the Challenged
POM Products treat, prevent, or reduce the risk of these diseases.”170
D. Cease and Desist Order
Having determined that POM violated the FTC Act in a serious,
deliberate, and consistent manner, the Commission affirmed the
ALJ’s cease and desist order.171 The Commission ordered that POM
“must have at least two RCTs before making any representation re-
garding a product’s effectiveness in the diagnosis, treatment, or pre-
vention of any disease.”172 The order applied to “any food, drug, or
164. In re Novartis Corp., 127 F.T.C. 580, 686 (1999) (citing FTC Deception Statement,
supra note 32, at 182).
165. POM II, supra note 12, at 39.
166. Id.
167. Id. at 40.
168. Id.
169. According to one POM conducted consumer research study, forty-seven percent
of the survey respondents that identified “health” as a reason for drinking pomegranate
juice further chose POM because it “helps protect against prostate cancer.” POM I, supra
note 26, at 293.
170. POM II, supra note 12, at 40 (internal citations omitted).
171. Id. at 49, 51.
172. Id. at 51. Commissioner Ohlhausen disagreed with the majority’s view that two
RCTs are warranted, and would have required one RCT and regarded the study in view of
other available scientific evidence. Id. at 51 n.36.
Requiring a second RCT is not reasonably related to the violations at issue in this
case because a second study would not cure any particular statistical or method-
ological problems. . . . Repetition or replication of poorly designed studies does
not make those studies sound. Moreover, although it might provide the Commis-
sion with some subjective comfort, requiring two RCTs does so at the expense of
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dietary supplement” made by the manufacturer.173 The Commission,
however, declined to impose the FDA pre-clearance requirement.174
Consequently, POM is permitted, with the appropriate substantiation,
to advertise that their products treat, prevent, or reduce the risk of a
disease without prior FDA approval.
Conclusion
In the Matter of POM Wonderful may have a significant and long-
lasting impact on advertisers in the booming food and dietary supple-
ment industry. Advertisers are paying close attention to this case as it
winds its way back into federal court. With this decision, the FTC has
taken the unprecedented step of holding food companies to stan-
dards that more closely resemble the standards applicable to pharma-
ceutical companies. Arguably, this step is in response to the evolving
understanding amongst Americans of the relationship between food,
diet, and health, in conjunction with the food industry’s desire to ex-
ploit this relationship.
What effect will this have on consumers? According to POM, who
intends to appeal the decision, this “new legal standard would require
food companies to conduct double-blind, placebo-controlled studies
in order to talk about potential health benefits of fruits and vegeta-
bles.”175 To POM, this represents a giant step backward in the cam-
paign to get Americans to eat healthier.176 This assumes, of course,
that Americans only reach for healthy foods when those foods claim to
treat, prevent, or reduce the risk of serious and potentially fatal dis-
limiting consumer access to potentially useful information. The product at issue is
an admittedly safe food product – a type of fruit juice. To set an unnecessarily
high bar for such a product is in tension with the balanced approach to substanti-
ation set forth in the Commission’s own Pfizer factors and with our policy commit-
ment to avoid imposing “unduly burdensome restrictions that might chill
information useful to consumers in making purchasing decisions.” To set an espe-
cially high bar without an adequate rationale also raises First Amendment con-
cerns. As the court in Pearson noted, “[t]he government insists that . . . the
commercial speech doctrine does not embody a preference for disclosure over
outright suppression. Our understanding of the doctrine is otherwise.” (internal
citations omitted).
Id.
173. Id. at 50.
174. Id. at 52.
175. Diane Suchetka, POM Wonderful Ordered to Stop Making Health Claims, CLEVE-
LAND.COM (Jan. 28, 2013), http://www.cleveland.com/healthfit/index.ssf/2013/01/pom_
wonderful_ordered_to_stop.html.
176. Id.
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eases. Apparently, merely being part of a healthy and well-balanced
diet doesn’t cut it anymore.
Congress could fairly easily enact a law that would provide clear
guidelines on the amount and type of evidence required to substanti-
ate a food health claim in a manner that is understood by consumers
and backed by good science. By differentiating between food and
drug manufacturers, such a law would encourage food companies to
raise awareness of the correlation between overall health and a bal-
anced diet. Without additional guidance from Congress, however, a
federal court may ultimately decide whether substantiation is only pos-
sible with an RCT.
Although consumer and industry groups are clashing over how
and if the government should regulate these claims, the need is clear.
If case-by-case litigation continues to define the parameters of permis-
sible claims, consumers will continue to be misled, and all brands will
pay the price.
806 UNIVERSITY OF SAN FRANCISCO LAW REVIEW [Vol. 47
